Introduction: Clinical studies have suggested efficacy of VEGF pathway inhibitors in the treatment of advanced neuroendocrine tumors (NETs).
Aim(s): We investigated the prognostic significance of expression of VEGF pathway components in NET patients generally, and in a subgroup of patients treated with bevacizumab.
Materials and methods: We evaluated immunohistochemical expression of VEGFA, VEGFR1, and VEGFR2 in a cohort of archival NETs and evaluated associations with overall survival (OS) and progression-free survival (PFS) after adjusting for other clinical prognostic variables.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr. Zhirong Qian
, Ter-Minassian M
, Chan J A
, Imamura Y U
, Hooshmand S M
, Brais L K
, Lin X
, Christiani D C
, Fuchs C S
, Ogino S
, Kulke M H
To read results and conclusion, please login ...
Further abstracts you may be interested in